Blog Archives

At-Home COVID Test

12/26/2020

Some experts believe home testing will be the key to end the pandemic, but there has been a lot of confusion on home testing due to differences in home collection vs actual testing.

Home collection kit - The LabCorp’s Pixel COVID-19 Test Home Collection Kit allows individuals to self-collect a nasal swab, then send it to LabCorp for testing without a doctor’s order. There are also other self collection kits for nasal and saliva that require a doctor’s order. The advantage of home collection kit is patients can avoid the long line at the drive thru collection site, the test will be performed by CLIA high complexity labs and using PCR which is more sensitive than antigen testing. One of the major disadvantages of home collection kits is turnaround time the patient must wait days for the lab to run the test.

Home testing kit - currently there are both FDA EUA molecular and antigen test kits available, the patient will collect and test the sample at their own home. With at home testing, the result is available in minutes to the individual. The Ellume antigen test is the only home test that doesn’t require a doctor’s order, both the Abbott BinaxNOW antigen test and Lucira Health molecular test required a doctor’s order. The sensitivity and detection limit is lower than lab performed PCR test.

Home testing supply is currently extremely limited and production is unlikely to ramp up until Spring of next year. Laboratory-based testing would still be a key to control the pandemic in the near future.

0 Comments

Is rapid COVID antigen testing the solution

12/25/2020

0 Comments

The COVID-19 testing supply chain had been under pressure almost a year now from swab, UTM, extraction reagent, pipette tip, analyzer, biosafety hood to COVID reagents. But the biggest shortage that remains unsolved is waived point of care (POC) molecular testing. Currently, all analyzers and test kits that’s capable of waived point of care COVID molecular testing are on backorder; there are labs with analyzers but unable to secure test kits and supplies isn’t guaranteed.
Antigen testing is emerging as an alternative as the supply problem with POC molecular testing challenge isn’t expected to be resolved anytime soon. Then comes the FDA warning letter in November alerting clinical labs and providers of false positive antigen tests. In the FDA letter the problems outlined included:

Test components not properly stored
The test kit being store opened prior to use
Failure to follow the manufacturer’s instruction of use
Reading the test before or after the specified time
Cross-contamination during testing due to insufficient cleaning of the work space, insufficient disinfection of the instrument and failure to change gloves between patient’s testing

As most worked in the laboratory field knows those errors are not new, they have been existent in point of care testing, when testing is not being performed by trained laboratory professionals, it’s not specific to COVID testing. Another challenge unique to COVID is normally POC testing is done in low volume and individually. For example, a medical assistant in a typical physician office would be testing one patient at a time, but with COVID healthcare professionals might find themselves performing multiple samples at the same time which lead to increased errors. CLIA/Medical directors need to realize performing waived COVID testing in mass screening is new to many healthcare professionals, it’s critical procedures and training be developed to migrate operator error. In the waived labs that we set up for COVID, we went above and beyond just the package insert but had created customized training checklist, quick reference guide, quiz and competency to ensure testing personnel are prepared to perform mass screening and produce accurate results.

0 Comments

Impact to waived lab with Lucira COVID-19 home use kit approval

12/6/2020

0 Comments

On 11/17/20 the FDA issued EUA to Lucira Health All-In-One Test Kit, this is the first test kit allowing anyone over 14 years old to perform self-testing at home. This is definitely a game-changer and many entrepreneurs planning to startup and mobile/pop up lab owners are trying to understand the impact this will have on their business model moving forward. While the technology and the FDA approval are a game changer, but the impact of Lucira approval will be likely minimal in the near future and shouldn’t discourage anyone from starting up a lab. There is still a lot of barriers to break through before the test can make an impact:

Authorized prescription is required
Only for patients suspected of COVID-19, not for asymptomatic testing
Availability is extremely limited
Insurance might not cover the cost of testing
No everyone is comfortable doing in-home testing
The estimated cost is about $50 or lower, but the exact cost is not confirmed

At home testing isn’t the end of the mobile/pop up COVID lab, there are still opportunities to open up your own mobile and pop up COVID lab.

0 Comments

Starting up new business ventures around COVID testing

12/3/2020

0 Comments

There are an increasing number of entrepreneurs wanting to start up new business ventures around COVID testing but without operating a lab. Some of the areas included:

Marketing
Supply chain
Logistics
IT/programming
Management services

Entrepreneurs usually feel very strongly about how their idea and business plan will work. Unfortunately, over 90% of the consultation calls involving business ideas that are illegal, some of the examples included:

Sharing/borrowing another lab CLIA license
Advertising testing service without a CLIA license
Advertising COVID test kit as their own company’s product when they are only a distributor
Obtaining CLIA for the purpose of specimen collection and referral testing only
Perform surveillance pool testing, but go back to individually test each sample without CLIA
Applying for CLIA before the lab is set up
Bypassing physician order requirements in state required order from a licensed provider
Having untrained personnel performs collection and testing
Have patient self-collect nasal swab when the test had not been approved by FDA for self-collection
Change the sample type from venipuncture whole blood to capillary blood when capillary blood sample isn’t listed as an acceptable sample type in the FDA approval

I have worked with clients where the only reason they start looking for a lab consultant is because they received a cease-and-desist letter from CMS or a notice from FDA their company website contains misleading information.
Hiring a lab consultant early on during the business planning process, not only can help entrepreneurs avoid legal actions by CMS, FDA, and State regulators. But an experienced lab consultant can provide valuable insight into the laboratory industry and help make connections.

At CLIA Lab Consultant, we provide startup consultation for $1,000 covering 2 hours of work, for the following topics: CLIA, CMS, State regulations (if applicable), FDA, EUA, Mobile/Temporary Site testing, OSHA, safety regulations, insurance, billing, ICD-10, CPT code and reimbursement.

0 Comments

CLIA Lab Consultant Blog

At-Home COVID Test

Is rapid COVID antigen testing the solution

Impact to waived lab with Lucira COVID-19 home use kit approval

Starting up new business ventures around COVID testing

Michael Yu, MS, MBA, MLS(ASCP)

Archives

Categories